Page last updated: 2024-10-29

ketanserin and Atrophy

ketanserin has been researched along with Atrophy in 1 studies

Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Svarer, C1
Madsen, K1
Hasselbalch, SG1
Pinborg, LH1
Haugbøl, S1
Frøkjaer, VG1
Holm, S1
Paulson, OB1
Knudsen, GM1

Trials

1 trial available for ketanserin and Atrophy

ArticleYear
MR-based automatic delineation of volumes of interest in human brain PET images using probability maps.
    NeuroImage, 2005, Feb-15, Volume: 24, Issue:4

    Topics: Aged; Aged, 80 and over; Aging; Algorithms; Atrophy; Brain; Brain Mapping; Cognition Disorders; Fema

2005